urology

What’s new in prostate Ca tests: Markers, imagingIn this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Biomarkers for bladder cancer: Current and futureThe role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
How to estimate life expectancy in men with localized prostate CaWhile no resource is perfect, it is worthwhile to familiarize yourself with some contemporary methodology and predictive tools to help determine life expectancy in localized prostate cancer patients.
Small molecule RNA inhibitor shows promise in PCaTargeted treatment with a small molecule RNA inhibitor demonstrates promising activity for promoting apoptosis of prostate cancer cells in culture, report investigators from Scripps Florida.
Combination immunotherapy may raise response rate in mRCC“The data from our study show that combination therapy [for metastatic renal cell carcinoma] may offer a much higher response rate with manageable side effects,” says study author Jianjun Gao, MD, PhD.
Survey of APPs highlights need for proper education
Age linked to decreased pelvic floor strengthA recent study found that decreased pelvic floor strength after childbirth is 2.5 times more likely to affect women over age 25 years than younger women.
Chemotherapy may harness immune system in bladder Ca“The immune system may be an under-recognized contributor to the tumor response to chemotherapy,” said researcher Philip H. Abbosh, MD, PhD.